Abrogation of Marek's disease virus replication using CRISPR/Cas9

被引:19
|
作者
Hagag, Ibrahim T. [1 ,2 ]
Wight, Darren J. [1 ]
Bartsch, Denise [3 ]
Sid, Hicham [3 ]
Jordan, Ingo [4 ]
Bertzbach, Luca D. [1 ]
Schusser, Benjamin [3 ]
Kaufer, Benedikt B. [1 ]
机构
[1] Free Univ Berlin, Inst Virol, Robert von Ostertag Str 7-13, D-14163 Berlin, Germany
[2] Zagazig Univ, Dept Virol, Fac Vet Med, El Tagneed St 114, Zagazig 44511, Egypt
[3] Tech Univ Munich, Sch Life Sci Weihenstephan, Reprod Biotechnol, Liesel Beckmann Str 1, D-85354 Freising Weihenstephan, Germany
[4] ProBioGen AG, Herbert Bayer Str 8, D-13086 Berlin, Germany
关键词
WEB TOOL; GENERATION; CHOPCHOP; BACTERIA; SEQUENCE;
D O I
10.1038/s41598-020-67951-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Marek's disease virus (MDV) is a highly cell-associated alphaherpesvirus that causes deadly lymphomas in chickens. While vaccination protects against clinical symptoms, MDV field strains can still circulate in vaccinated flocks and continuously evolve towards greater virulence. MDV vaccines do not provide sterilizing immunity, allowing the virus to overcome vaccine protection, and has increased the need for more potent vaccines or alternative interventions. In this study, we addressed if the CRISPR/Cas9 system can protect cells from MDV replication. We first screened a number of guide RNAs (gRNAs) targeting essential MDV genes for their ability to prevent virus replication. Single gRNAs significantly inhibited virus replication, but could result in the emergence of escape mutants. Strikingly, combining two or more gRNAs completely abrogated virus replication and no escape mutants were observed upon serial passaging. Our study provides the first proof-of-concept, demonstrating that the CRISPR/Cas9 system can be efficiently used to block MDV replication. The presented findings lay the foundation for future research to completely protect chickens from this deadly pathogen.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Abrogation of Marek’s disease virus replication using CRISPR/Cas9
    Ibrahim T. Hagag
    Darren J. Wight
    Denise Bartsch
    Hicham Sid
    Ingo Jordan
    Luca D. Bertzbach
    Benjamin Schusser
    Benedikt B. Kaufer
    Scientific Reports, 10
  • [2] Development of CRISPR/Cas9 transgenes to target Marek's disease herpesvirus in chickens
    Challagulla, A.
    Jenkins, K.
    Schat, K. A.
    Doran, T. J.
    TRANSGENIC RESEARCH, 2018, 27 (05) : 473 - 473
  • [3] Marek's disease virus as a CRISPR/Cas9 delivery system to defend against avian leukosis virus infection in chickens
    Liu, Yongzhen
    Xu, Zengkun
    Zhang, Yu
    Yu, Mengmeng
    Wang, Suyan
    Gao, Yulong
    Liu, Changjun
    Zhang, Yanping
    Gao, Li
    Qi, Xiaole
    Cui, Hongyu
    Pan, Qing
    Li, Kai
    Wang, Xiaomei
    VETERINARY MICROBIOLOGY, 2020, 242
  • [4] Targeted Editing of the pp38 Gene in Marek's Disease Virus-Transformed Cell Lines Using CRISPR/Cas9 System
    Zhang, Yaoyao
    Luo, Jun
    Tang, Na
    Teng, Man
    Reddy, Vishwanatha R. A. P.
    Moffat, Katy
    Shen, Zhiqiang
    Nair, Venugopal
    Yao, Yongxiu
    VIRUSES-BASEL, 2019, 11 (05):
  • [5] Application of CRISPR/Cas9 in Alzheimer's Disease
    Lu, Likui
    Yu, Xi
    Cai, Yongle
    Sun, Miao
    Yang, Hao
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [6] Prevention of Avian Retrovirus Infection in Chickens Using CRISPR-Cas9 Delivered by Marek's Disease Virus
    Li, Kai
    Liu, Yongzhen
    Xu, Zengkun
    Zhang, Yu
    Yao, Yongxiu
    Nair, Venugopal
    Liu, Changjun
    Zhang, Yanping
    Gao, Yulong
    Qi, Xiaole
    Cui, Hongyu
    Gao, Li
    Wang, Xiaomei
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2020, 21 : 343 - 353
  • [7] Selection of Vaccinia Virus Recombinants Using CRISPR/Cas9
    Gowripalan, Anjali
    Smith, Stewart A.
    Tscharke, David C.
    BIO-PROTOCOL, 2021, 11 (24):
  • [8] CRISPR/Cas9 Toolbox for the Study of Parkinson's Disease
    Sandoval, I. M.
    Daley, B.
    Kuhn, N.
    Marckini, N.
    Strauss, A. C.
    Lipton, J. W.
    Manfredsson, F. P.
    Collier, T. J.
    CELL TRANSPLANTATION, 2016, 25 (04) : 771 - 771
  • [9] Using CRISPR/Cas9 to model human liver disease
    Alves-Bezerra, Michele
    Furey, Nika
    Johnson, Collin G.
    Bissig, Karl-Dimiter
    JHEP REPORTS, 2019, 1 (05) : 392 - 402
  • [10] CRISPR/Cas9 nickase-mediated inactivation of hepatitis B virus replication
    Karimova, M.
    Beschorner, N.
    Dammermann, W.
    Chemnitz, J.
    Indenbirken, D.
    Grundhoff, A.
    Lueth, S.
    Buchholz, F.
    zur Wiesch, J. Schulze
    Hauber, J.
    JOURNAL OF VIRAL HEPATITIS, 2015, 22 : 31 - 31